Detalles de la búsqueda
1.
Efficacy and Safety of Elafibranor in Primary Biliary Cholangitis.
N Engl J Med;
390(9): 795-805, 2024 Feb 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-37962077
2.
An Open Label, Randomized, Multicenter Study of Elafibranor in Children With Nonalcoholic Steatohepatitis.
J Pediatr Gastroenterol Nutr;
77(2): 160-165, 2023 08 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37084342
3.
The acyclic CB1R inverse agonist taranabant mediates weight loss by increasing energy expenditure and decreasing caloric intake.
Cell Metab;
7(1): 68-78, 2008 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-18177726
4.
Human abuse potential and cognitive effects of taranabant, a cannabinoid 1 receptor inverse agonist: a randomized, double-blind, placebo- and active-controlled, crossover study in recreational polydrug users.
J Clin Psychopharmacol;
32(4): 492-502, 2012 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-22722508
5.
Neuropeptide Y5 receptor antagonism does not induce clinically meaningful weight loss in overweight and obese adults.
Cell Metab;
4(4): 275-82, 2006 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-17011500
6.
Metabolism and excretion of [14C]taranabant, a cannabinoid-1 inverse agonist, in humans.
Xenobiotica;
40(10): 691-700, 2010 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-20722472
7.
Single-dose administration of MK-0657, an NR2B-selective NMDA antagonist, does not result in clinically meaningful improvement in motor function in patients with moderate Parkinson's disease.
J Clin Pharmacol;
49(7): 856-64, 2009 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-19491335
8.
Safety, tolerability, pharmacokinetics, and pharmacodynamic properties of taranabant, a novel selective cannabinoid-1 receptor inverse agonist, for the treatment of obesity: results from a double-blind, placebo-controlled, single oral dose study in healthy volunteers.
J Clin Pharmacol;
48(4): 418-27, 2008 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-18258750
9.
Multiple-dose pharmacokinetics, pharmacodynamics, and safety of taranabant, a novel selective cannabinoid-1 receptor inverse agonist, in healthy male volunteers.
J Clin Pharmacol;
48(6): 734-44, 2008 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-18508950
10.
Value-based health insurance design: how much does socioeconomic status matter?
Am J Manag Care;
24(7): 318-321, 2018 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-30020750
11.
Association of Wage With Employee Participation in Health Assessments and Biometric Screening.
Am J Health Promot;
32(2): 440-445, 2018 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-28535717
12.
High intensity lifestyle intervention and long-term impact on weight and clinical outcomes.
PLoS One;
13(4): e0195794, 2018.
Artículo
en Inglés
| MEDLINE | ID: mdl-29668741
13.
Health Care Use And Spending Patterns Vary By Wage Level In Employer-Sponsored Plans.
Health Aff (Millwood);
36(2): 250-257, 2017 02 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28167713
14.
Single and multiple dose pharmacokinetics and pharmacodynamics of omarigliptin, a novel, once-weekly dipeptidyl peptidase-4 inhibitor, in healthy Japanese men.
J Diabetes Investig;
8(1): 84-92, 2017 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-27182005
15.
Acetyl CoA Carboxylase Inhibition Reduces Hepatic Steatosis but Elevates Plasma Triglycerides in Mice and Humans: A Bedside to Bench Investigation.
Cell Metab;
26(2): 394-406.e6, 2017 Aug 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28768177
16.
Effects of Age, Sex, and Obesity on the Single-Dose Pharmacokinetics of Omarigliptin in Healthy Subjects.
Clin Pharmacol Drug Dev;
5(5): 374-82, 2016 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-27627193
17.
Pharmacokinetic and Pharmacodynamic Effects of Multiple-dose Administration of Omarigliptin, a Once-weekly Dipeptidyl Peptidase-4 Inhibitor, in Obese Participants With and Without Type 2 Diabetes Mellitus.
Clin Ther;
38(3): 516-30, 2016 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-26869191
18.
Pharmacokinetics and Pharmacodynamics of Omarigliptin, a Once-Weekly Dipeptidyl Peptidase-4 (DPP-4) Inhibitor, After Single and Multiple Doses in Healthy Subjects.
J Clin Pharmacol;
56(12): 1528-1537, 2016 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-27225334
19.
Recombinant methionyl human leptin administration to achieve high physiologic or pharmacologic leptin levels does not alter circulating inflammatory marker levels in humans with leptin sufficiency or excess.
J Clin Endocrinol Metab;
90(3): 1618-24, 2005 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-15613407
20.
Plasma adiponectin concentrations in relation to endometrial cancer: a case-control study in Greece.
J Clin Endocrinol Metab;
88(3): 993-7, 2003 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-12629074